Pharmacogenetics for individualized cancer chemotherapy

Publication type:
Journal article
Metadata:
Autoren
  • T Efferth
  • M Volm
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000234189900002&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.1016/j.pharmthera.2005.02.005
Externe Identifier
  • Clarivate Analytics Document Solution ID: 996QS
  • PubMed Identifier: 15890408
ISSN
0163-7258
Ausgabe der Veröffentlichung
2
Zeitschrift
PHARMACOLOGY & THERAPEUTICS
Schlüsselwörter
  • cancer drug resistance
  • single nucleotide polymorphisms
  • toxicity
Paginierung
155 - 176
Datum der Veröffentlichung
2005
Status
Published
Titel
Pharmacogenetics for individualized cancer chemotherapy
Sub types
  • Review
Ausgabe der Zeitschrift
107

Data source: Web of Science (Lite)

Other metadata sources:
Autoren
  • Thomas Efferth
  • Manfred Volm
DOI
10.1016/j.pharmthera.2005.02.005
ISSN
0163-7258
Ausgabe der Veröffentlichung
2
Zeitschrift
Pharmacology & Therapeutics
Sprache
en
Paginierung
155 - 176
Datum der Veröffentlichung
2005
Status
Published
Herausgeber
Elsevier BV
Herausgeber URL
http://dx.doi.org/10.1016/j.pharmthera.2005.02.005
Datum der Datenerfassung
2024
Titel
Pharmacogenetics for individualized cancer chemotherapy
Ausgabe der Zeitschrift
107

Data source: Crossref

Abstract
The same doses of medication cause considerable heterogeneity in efficacy and toxicity across human populations. Genetic factors are thought to represent important determinants of drug efficacy and toxicity. Pharmacogenetics focuses on the prediction of the response of tumor and normal tissue to standard therapy by genetic profiling and, thereby, to select the most appropriate medication at optimal doses for each individual patient. In the present review, we discuss the relevance of single nucleotide polymorphisms (SNP) in genes, whose gene products act upstream of the actual drug target sites, that is, drug transporters and drug metabolizing phase I and II enzymes, or downstream of them, that is, apoptosis-regulating genes and chemokines. SNPs in relevant genes, which encode for proteins that interact with anticancer drugs, were also considered, that is, enzymes of DNA biosynthesis and metabolism, DNA repair enzymes, and proteins of the mitotic spindle. A significant body of evidence supports the concept of predicting drug efficacy and toxicity by SNP genotyping. As the efficacy of cancer chemotherapy, as well as the drug-related toxicity in normal tissues is multifactorial in nature, sophisticated approaches such as genome-wide linkage analyses and integrate drug pathway profiling may improve the predictive power compared with genotyping of single genes. The implementation of pharmacogenetics into clinical routine diagnostics including genotype-based recommendations for treatment decisions and risk assessment for practitioners represents a challenge for the future.
Addresses
  • German Cancer Research Center, M070, Im Neuenheimer Feld 282, 69120 Heidelberg, Germany. thomas.efferth@web.de
Autoren
DOI
10.1016/j.pharmthera.2005.02.005
eISSN
1879-016X
Externe Identifier
  • PubMed Identifier: 15890408
Open access
false
ISSN
0163-7258
Ausgabe der Veröffentlichung
2
Zeitschrift
Pharmacology & therapeutics
Schlüsselwörter
  • Animals
  • Humans
  • Neoplasms
  • Antineoplastic Agents
  • Pharmacogenetics
  • Biotransformation
  • Drug Resistance, Neoplasm
  • Polymorphism, Genetic
Sprache
eng
Medium
Print
Paginierung
155 - 176
Datum der Veröffentlichung
2005
Status
Published
Datum der Datenerfassung
2005
Titel
Pharmacogenetics for individualized cancer chemotherapy.
Sub types
  • Review
  • Journal Article
Ausgabe der Zeitschrift
107

Data source: Europe PubMed Central

Abstract
The same doses of medication cause considerable heterogeneity in efficacy and toxicity across human populations. Genetic factors are thought to represent important determinants of drug efficacy and toxicity. Pharmacogenetics focuses on the prediction of the response of tumor and normal tissue to standard therapy by genetic profiling and, thereby, to select the most appropriate medication at optimal doses for each individual patient. In the present review, we discuss the relevance of single nucleotide polymorphisms (SNP) in genes, whose gene products act upstream of the actual drug target sites, that is, drug transporters and drug metabolizing phase I and II enzymes, or downstream of them, that is, apoptosis-regulating genes and chemokines. SNPs in relevant genes, which encode for proteins that interact with anticancer drugs, were also considered, that is, enzymes of DNA biosynthesis and metabolism, DNA repair enzymes, and proteins of the mitotic spindle. A significant body of evidence supports the concept of predicting drug efficacy and toxicity by SNP genotyping. As the efficacy of cancer chemotherapy, as well as the drug-related toxicity in normal tissues is multifactorial in nature, sophisticated approaches such as genome-wide linkage analyses and integrate drug pathway profiling may improve the predictive power compared with genotyping of single genes. The implementation of pharmacogenetics into clinical routine diagnostics including genotype-based recommendations for treatment decisions and risk assessment for practitioners represents a challenge for the future.
Date of acceptance
2005
Autoren
  • Thomas Efferth
  • Manfred Volm
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/15890408
DOI
10.1016/j.pharmthera.2005.02.005
ISSN
0163-7258
Ausgabe der Veröffentlichung
2
Zeitschrift
Pharmacol Ther
Schlüsselwörter
  • Animals
  • Antineoplastic Agents
  • Biotransformation
  • Drug Resistance, Neoplasm
  • Humans
  • Neoplasms
  • Pharmacogenetics
  • Polymorphism, Genetic
Sprache
eng
Country
England
Paginierung
155 - 176
PII
S0163-7258(05)00057-4
Datum der Veröffentlichung
2005
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2005
Titel
Pharmacogenetics for individualized cancer chemotherapy.
Sub types
  • Journal Article
  • Review
Ausgabe der Zeitschrift
107

Data source: PubMed

Beziehungen:
Property of

Tools